News
SVF Vaccines Announces CEO Transition
Stockholm, Sweden; November 15, 2024.
SVF Vaccines AB, a Swedish R&D company focusing on the discovery and development of vaccines to treat and prevent life-threatening viral infections, today announces that Dr Richard Bethell has decided to step down as CEO of the company in order to pursue other professional interests. The board of SVF Vaccines has appointed Dr Gaston Picchio as acting CEO with effect from today, Friday November 15 th. Dr Bethell will remain associated with the company in an advisory role.
Read the full Pressrelease below
Svenska Vaccinfabriken granted US-patent regarding chimeric genes for immunotherapy against chronic hepatitis B and D virus infections
The 2nd of February 2021, SVF was granted a U.S patent (No: 10,905,760) covering chimeric genes and polypeptides that are useful for the generation, enhancement, or improvement of the immune response to chronic hepatitis B and D virus infections.
SVF Vaccines announces positive clinical safety and immunogenicity data from the Phase 1 study of its universal Covid-19 vaccine, SVF-002
Stockholm, Sweden; October 21, 2024.
SVF Vaccines AB announces positive clinical safety and immunogenicity data following completion of the Phase 1 study of its universal Covid-19 vaccine, SVF-002. SVF-002 is a DNA vaccine that has been designed to elicit a broad neutralizing antibody response directed against the Spike (S) protein of SARS-CoV-2, the virus that causes Covid-19, as well as T cell responses against highly conserved components of the virus, the membrane protein (M) and the nucleoprotein (N). In preclinical studies, SVF-002 induced a strong antibody response to SARS-CoV-2, and broad T-cell responses against beta-coronaviruses, with similar levels of activity against SARS-CoV-2 and an unrelated coronavirus isolated from bats.
Read the full Pressrelease below
SVF Vaccines announces the start of a Phase 1 study of its universal Covid-19 vaccine
Stockholm, Sweden; February 28, 2023.
SVF Vaccines AB, formerly Svenska Vaccinfabriken Produktion AB, announces that the first subject has been dosed with its universal Covid-19 vaccine (SVF-002). SVF-002, which has been developed and evaluated by the Horizon 2020 funded OpenCorona project, has been designed to elicit a strong neutralizing antibody response directed against the Spike (S) protein of SARS-CoV-2, the virus that causes Covid-19. Neutralizing antibodies directed against the S protein are known to be correlated with protection against the disease. However the S protein is highly variable, allowing escape variants to emerge. Unlike approved Covid-19 vaccines, SVF-002 contains three different variants of the receptor binding domain of the spike in combination with two other viral proteins. The vaccine has been designed to induce both neutralizing antibodies and T-cell responses to parts of the virus that are genetically stable and capable of eliminating cells in which the virus is present. This is thought to be especially important for clearing infections in people whose antibody response to vaccination is poor. By directing this T-cell response against parts of the virus that are much more highly conserved,
Read the full Press release below
Swedish Vaccine Factory participating in EASL 2022 in London
SVF will be presenting some of the latest results from the hepatitis B and D therapeutic vaccine development at #EASL2022 #ILC2022 in London June 22-26, 2022.
The abstract is entitled “Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection”.
Svenska Vaccinfabriken tar upp kampen mot hepatit D
Det är drygt 30 år sedan forskare lyckades bekräfta existensen av hepatit C-viruset. Det var ett första viktigt steg för att hjälpa de miljontals människor som föll offer för dess dödliga verkan. Nu har Karolinska Developments portföljbolag Svenska Vaccinfabriken riktat in sig på virusets aggressiva kusin, hepatit D, i hoppet om att kunna utveckla ett botemedel.
Vi pratar 2021 med Vaccinfabriken
Med en tillökning om hela 40 nya medlemmar under 2020 får SwedenBIO både en ökad tyngd i att föra branschens talan men också som plattform för er medlemmar att nätverka med varandra. Vad ser en av våra nyaste medlemmar Vaccinfabriken för möjligheter under 2021 och vad har de för förväntan på medlemskapet?